Category: Content
This category defines content that can be used throughout the website. So for example an article, a report, a file,… i.e. a press release can be displayed on the “press release” page but the newest press release is also displayed on the homepage.
ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019
Geneva, Switzerland and Boston, MA – August 5, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
Geneva, Switzerland and Boston, MA – July 26, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
CEO Office
+41 (0)22 552 1550 contact@obseva.ch
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
Geneva, Switzerland and Boston, MA – July 18, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban
Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019 GENEVA, Switzerland and BOSTON, MA…
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City
Geneva, Switzerland and Boston, MA – July 12, 2019– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the…
ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids
Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs
Geneva, Switzerland and Boston, MA – July 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna
ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna Geneva,…